Beverly Hills MD Dermal Repair Complex: A Doctor-Recommended Solution for Radiant, Youthful-Looking Skin To Help You Celebrate National Women's Health Week
BEVERLY HILLS, Calif., May 11, 2025 /PRNewswire/ -- During National Women's Health Week, there's no better time to recognize an often-overlooked part of women's well-being: skin health. While many women turn to creams and serums to address the appearance of fine lines, sagging, or dullness, few realize that many visible signs of aging begin beneath the surface. These signs are often triggered by internal factors like hormonal changes, collagen depletion, and nutritional gaps. True skin health goes beyond what we put on our faces; it starts within.
That's the perspective behind Beverly Hills MD® Dermal Repair Complex™, a supplement developed by Beverly Hills MD founders and cosmetic surgeons Dr. Payman Danielpour and Dr. John Layke. After years of treating patients in their practice, they saw firsthand how supporting the body's natural internal processes could lead to deeper, more lasting improvements in skin appearance. Dermal Repair Complex reflects their approach, offering targeted nutrients to help combat the internal causes of visible aging and support healthier-looking, more resilient skin over time.†*
What Is Beverly Hills MD Dermal Repair Complex?Beverly Hills MD Dermal Repair Complex is a cutting-edge dietary supplement designed to address the root causes of visible aging by nourishing skin from the inside out. Unlike topical products that only treat surface-level concerns, this daily supplement works internally to support the body's natural ability to maintain firm, hydrated, and youthful-looking skin. Dermal Repair Complex uses a blend of scientifically studied ingredients to help combat age-related collagen loss, reduce the visible effects of hormonal imbalances, and protect against free radical damage. Regular use may result in a smoother, firmer appearance, particularly in areas prone to sagging like the cheeks, jawline, and neck, along with a noticeable improvement in skin tone, texture, and overall radiance. This doctor-developed formula doesn't just stop at the skin—it can also support stronger nails and thicker-looking hair, helping women feel vibrant and healthy from head to toe.†*
What Are the Key Ingredients in Beverly Hills MD Dermal Repair Complex?Dermal Repair Complex is formulated with ingredients known for their ability to support youthful skin and help fight visible aging at its source.
Hydrolyzed Collagen: This highly absorbable form of collagen supplies the skin with essential amino acids that help maintain firmness and elasticity, supporting a more lifted, youthful appearance over time.†*
Saw Palmetto: A botanical extract known for helping reduce some of the negative effects of DHT (dihydrotestosterone), a hormone that can accelerate skin aging. Saw Palmetto helps reduce the hormonal triggers that can contribute to the appearance of sagging and loss of skin density.†*
MSM (Methylsulfonylmethane): A natural compound that supports the skin's structure by supporting collagen production and improving skin resilience. MSM can also help promote better tone and texture by supporting the skin's underlying matrix.†*
To learn more about how Dermal Repair Complex can support your wellness and skin goals this National Women's Health Week, visit beverlyhillsmd.com.
Beverly Hills MD Dermal Repair Complex Reviews
"I'm 54 and my skin feels the best it has ever felt my face feels more plump and my fine lines aren't as noticeable as they were 5 months ago this magic in a jar" - Carolyn (April, 2025)
"I've been using Dermal repair for several months now. I'm pleased with results thus far. My skin is resilient, and glowing these days. My creases at my howled seem softer along with my lip lines softening. I get a facial monthly and my technician has commented on the improvement in my skin." - Rebecca (April, 2025)
"At seventy years old my skin has not looked better. Even my husband talks about how soft and smooth my skin is. It's been nice to have this positive aspect in my older years" - Rosemary (March, 2025)
Beverly Hills MD Dermal Repair Complex FAQ
How do I use Beverly Hills MD Dermal Repair Complex?
For optimal results, take 2 capsules of Dermal Repair Complex dietary supplement daily with 8 fl. oz. of water and a meal.
Where can I buy Beverly Hills MD Dermal Repair Complex?
Beverly Hills MD Dermal Repair Complex can be purchased on the Beverly Hills MD website for the purchase price of $58.00 with a 90-day money-back guarantee (less s&h).
About Dr. Layke and Dr. DanielpourDr. John Layke and Dr. Payman Danielpour are renowned plastic surgeons and co-founders of the Beverly Hills Plastic Surgery Group. Both doctors trained at the prestigious Long Island Plastic Surgical Group before offering world-class procedures at their Beverly Hills clinic. In 2014, their passion for science inspired them to develop advanced ingredient formulations to help users achieve results in the comfort of their homes, and the Beverly Hills MD skincare line was born. Dr. John Layke and Payman Danielpour also launched the Forever Young Podcast, where they discuss beauty trends and longevity solutions. For more, follow them on their Forever Young YouTube channel, Instagram @plastixdocs, and TikTok.
About Beverly Hills MDBeverly Hills MD was created by Dr. John Layke and Dr. Payman Danielpour of the innovative Beverly Hills Plastic Surgery Group. With their cutting-edge skincare line, Beverly Hills MD, they reach beyond the walls of their office and offer at-home "look younger" results to those seeking the best at-home solutions available. Each product works to visibly correct the most stubborn skincare concerns. Their bestsellers include Deep Wrinkle Filler and Rapid-Lift Advanced Neck Serum. For the latest news, follow Beverly Hills MD on Instagram @officialbhmd and YouTube.
*All individuals are unique. Results can and will vary.
✝ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Media Contact:Shari Mesulamshari@themesulamgroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/beverly-hills-md-dermal-repair-complex-a-doctor-recommended-solution-for-radiant-youthful-looking-skin-to-help-you-celebrate-national-womens-health-week-302451640.html
SOURCE Beverly Hills MD
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound
By Maggie Fick and Bhanvi Satija SEATTLE (Reuters) -U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. U.S. list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4% after 72 weeks in a trial. That compares with weight loss of 15% for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21%. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is "probably going to come on par with the current drugs today or slightly lower," Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. GROWING CASH PAY U.S. doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40% of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce U.S. prices. Novo declined to comment on pricing, pointing to August 6 comments by David Moore, its U.S. operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. MANUFACTURING VOLUME A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the U.S. market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. "It's all about scale and pricing," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. "Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy," Andersen added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Forest Lake Endodontics Welcomes Endodontist Dr. Linda Liu to the Practice
FOREST LAKE, Minn., Aug. 18, 2025 /PRNewswire/ -- Forest Lake Endodontics in Forest Lake, Minnesota, announced today that endodontist Dr. Linda Liu has joined its team, bringing advanced training in root canal treatment and a strong commitment to patient-centered care. Dr. Liu earned her Bachelor of Science in Microbiology with a minor in Mathematics from the University of Michigan in Ann Arbor. She went on to obtain her Doctor of Dental Surgery degree and complete a General Practice Residency at the University of Toledo. Dr. Liu then specialized in Endodontics at the University of Minnesota, where she also earned her Master's degree. Residing in Blaine with her husband, Philip, an anesthesiology resident at the University of Minnesota, and their goldendoodle, Dr. Liu looks forward to serving patients in the greater Forest Lake community. Outside of her professional life, she enjoys playing the piano, pickleball, traveling to new destinations, and exploring local restaurants. Forest Lake Endodontics has served the Twin Cities metro area for 6 years, specializing in root canal therapy and other advanced endodontic treatments in a welcoming environment. The practice partners closely with referring dentists to provide patients with seamless, high-quality care. "I am honored to join the talented team at Forest Lake Endodontics," said Dr. Liu. "It is incredibly rewarding to relieve patients' discomfort and preserve their natural teeth. I look forward to contributing my skills and working alongside my colleagues to deliver the highest level of care." Forest Lake Endodontics provides the following services: Root canal treatment. Root canal retreatment. Endodontic surgery (apicoectomy). Emergency dental care for traumatic injuries. Advanced diagnostics for tooth pain. External root resorption repairs. About Forest Lake Endodontics Forest Lake Endodontics specializes in advanced endodontic treatments designed to save natural teeth and restore oral health. The practice combines cutting-edge technology with a patient-first philosophy to deliver exceptional results. For more information, visit or contact Forest Lake Endodontics, 1420 Lake Street S., Suite 200a, Forest Lake, MN 55025, 651-464-9888. View original content to download multimedia: SOURCE Forest Lake Endodontics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 minutes ago
- Associated Press
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Ben Hwang, Ph.D., Profusa's Chairman and CEO - 'We estimate a $10.5B+ global addressable market for our tissue oxygen technology across three indications – peripheral artery disease, chronic wounds, and critical limb ischemia. In Europe, the clinical need comes to over 300,000 endovascular procedures a year. We look forward to bringing our differentiated, next generation biosensor technology to address this market need. The obesity treatment market is exploding, with Goldman Sachs projecting it to reach $130 billion by 2030. Driven by rising global obesity rates—now at 42% of U.S. adults, per the CDC—the sector has become a magnet for investors seeking exposure to transformative medicine. The current wave is led by GLP-1 receptor agonists such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which deliver 15–20% body-weight reductions in trials and billions in sales—Wegovy alone brought in $8.4 billion in 2024. The next frontier is oral formulations and complementary technologies that improve patient compliance and expand access, where smaller innovators like VKTX, PFSA, and GPCR are working to carve out market share. Macro tailwinds are strong: aging populations, increased payer willingness to cover weight-loss drugs, policy boosts like the MAHA mandate, and the White House's push for wearable health devices. The diabetes market—tightly linked to obesity—is also projected to hit $54 billion, offering dual-use opportunities for versatile platforms. Investor interest is clear in the sector's high trading volumes and volatility. When Pfizer halted its GLP-1 pill over safety concerns, Viking Therapeutics (NASDAQ: VKTX) and Structure Therapeutics (NASDAQ: GPCR) jumped 19.2% and 10.6% in a single day—evidence of how quickly sentiment can shift and how sharply the right catalysts can move these names. Profusa, Inc. (NASDAQ: PFSA) is a California-based innovator developing CE Mark-approved, bioengineered implantable biosensors for continuous, clinical-grade biochemical monitoring. Its flagship Lumee Oxygen Platform integrates directly into the body to measure critical metrics such as tissue oxygen and, potentially, glucose—a capability that could prove vital in upcoming triple-agonist obesity drug trials, where real-time glucose tracking can help mitigate hypoglycemia risks. The Lumee platform is slated for commercial launch in the EU in Q1 2026 through a Spanish distributor, with a U.S. pivotal trial and FDA submission targeted for mid-2026. Beyond obesity trials, the same core technology addresses major markets in chronic disease management and could benefit from policy tailwinds, including the MAHA initiative and the White House's national push to integrate advanced wearables into healthcare. Trading at $0.49 with a $16.82 million market cap, PFSA operates with just two employees, an 85% reduction in quarterly net loss, and a commercialization timeline now measured in quarters, not decades. Recent momentum indicators show bullish divergence, suggesting potential technical upside. With exposure to disruptive biosensing PFSA stands is part of a powerful megatrend—positioning it as a sleeper stock with outsized re-rating potential. Overall, the obesity treatment sector is at a tipping point, driven by blockbuster GLP-1 drugs, the promise of oral therapies, and supportive policy shifts like the MAHA initiative and federal wearable integration. With the market projected to reach $130 billion by 2030, companies innovating in this space are positioned for explosive growth. Viking Therapeutics (VKTX), Profusa (PFSA), and Structure Therapeutics (GPCR) each bring unique strengths: Viking's dual-formulation VK2735, Profusa's biosensor platform for trial support and chronic disease management, and Structure's oral GLP-1 candidate aleniglipron. High trading volumes and volatility reflect the market's keen interest in these names, offering investors a chance to ride the wave of a transformative healthcare revolution. Whether through clinical breakthroughs or strategic partnerships, these stocks are primed to shape the future of obesity treatment. Source: Disclaimer: This analysis is for informational purposes only and should not be considered as investment advice. Always conduct your own research and consult with financial advisors before making investment decisions. Clinical-stage pharmaceutical companies carry significant risks, and there can be no assurance of successful drug development or regulatory approval. This blog post is for informational purposes only and does not constitute financial advice or an endorsement of COEP or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated one thousand five hundred dollars by a 3rd party EDM Media for content distribution services on PFSA for August 18th, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions. Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: [email protected] City: Frisco State: Texas Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
